News >

Pegram Highlights Progress in HER2+ Breast Cancer

Danielle Bucco
Published: Monday, Apr 09, 2018

Mark Pegram, MD

Mark Pegram, MD
It is an exciting time in drug development for patients with HER2-positive breast cancer, which is leading to new therapeutic strategies and FDA approvals, says Mark D. Pegram, MD.

on Breast Cancer, Pegram, associate director for clinical research and director of the breast oncology program at Stanford Women’s Cancer Center, discussed the evolving treatment paradigm of HER2-positive breast cancer.

OncLive: Please provide an overview of your presentation on HER2-positive breast cancer.

Pegram: It is a very exciting time in drug development for patients with HER2-positive breast cancer. We have seen recent FDA approvals for new approaches to treat patients with early-stage HER2-positive breast cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x